SlpA-Expressing Probiotics for C. difficile Colonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infection (CDI) are inadequate, as antibiotics alter the gut microbiome and do not effectively prevent colonization, leading to significant healthcare costs and disease burden.
Innovation Solution
Probiotic bacteria such as Lactococcus lactis and Lactobacillus acidophilus are engineered to express the Clostridium difficile surface protein SlpA or its chimeric variants, which are administered to the gut to treat or prevent CDI by colonizing and competing with pathogenic bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat C. difficile infection, then bacterial infection is suppressed, but the gut microbiome composition is altered and colonization resistance is reduced
Solution Approach 1:
The patent uses engineered probiotic bacteria as an intermediary organism that expresses C. difficile SlpA protein. These probiotics act as a mediator to compete with C. difficile for colonization sites without directly applying antibiotics, thereby suppressing infection while preserving the natural microbiome composition and avoiding the harmful effects of antibiotic-induced microbiome disruption
Solution Approach 2:
The invention takes the harmful SlpA adhesin protein from C. difficile and converts it into a beneficial tool by having probiotic bacteria express this protein. The probiotics use the pathogen's own adhesin to outcompete C. difficile for binding sites on intestinal epithelial cells, effectively turning the pathogen's weapon against it while avoiding antibiotic use
2Object-affected harmful factors
If vaccines are developed to prevent C. difficile disease, then disease symptoms are reduced, but colonization by C. difficile is not prevented
Solution Approach 1:
The patent employs probiotic bacteria that preemptively occupy colonization sites on intestinal epithelial cells before C. difficile can establish infection. By expressing SlpA adhesin, the probiotics perform preliminary action of binding to epithelial cells and blocking access to C. difficile, preventing both colonization and subsequent disease symptoms
3Reliability
If probiotic bacteria express C. difficile SlpA protein, then colonization competition is enhanced, but genetic engineering complexity increases
Solution Approach 1:
The patent extracts only the essential SlpA adhesin protein expression capability from C. difficile and transfers this specific function to probiotic bacteria through genetic engineering. Rather than transferring entire pathogenicity factors, only the colonization-related SlpA gene is isolated and expressed in the probiotic host, minimizing genetic complexity while maximizing colonization competition
Solution Approach 2:
The invention applies local quality by giving the probiotic bacteria a specific localized function - expression of SlpA adhesin on their surface - without requiring comprehensive genetic modification. The probiotics maintain their native beneficial properties while acquiring the specific local capability to compete with C. difficile through SlpA-mediated adhesion
Data Source
AI summary
The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.